Subsequently, TFE3 and TFEB were grouped together under the title “MITF/TFE translocation renal carcinoma” in the 2016 WHO classification [11] and then were separated into two distinct molecularly-defined entities in the recent WHO classification, 2022, as TFE3-rearranged RCC and TFEB-rearranged RCC [12]. This evidence concerns the gene MITF and renal cell carcinoma.